Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Vincent Nicolaï"'
Autor:
Antoine Vasseur, Matthieu Carton, Severine Guiu, Paule Augereau, Lionel Uwer, Marie-Ange Mouret-Reynier, Christelle Levy, Jean-Christophe Eymard, Jean-Marc Ferrero, Marianne Leheurteur, Anthony Goncalves, Marie Robert, Thibault De La Motte Rouge, Thomas Bachelot, Thierry Petit, Marc Debled, Thomas Grinda, Isabelle Desmoulins, Laurence Vanlemmens, Vincent Nicolaï, Gaëtane Simon, Luc Cabel
Publikováno v:
Breast, Vol 65, Iss , Pp 136-144 (2022)
Background: Taxanes are one of the most effective chemotherapies (CT) in breast cancer (BC), but the efficacy of taxanes rechallenge in early metastatic relapse has been poorly studied in patients previously treated by taxanes in the (neo)adjuvant se
Externí odkaz:
https://doaj.org/article/3e5e3d1b6d254f9091fd5376422aa2e4
Autor:
Anne-Cécile Brunac, Joanna Fourquet, Gaëlle Perot, Marion Jaffrelot, Julie Meilleroux, Marie Danjoux, Thomas Filleron, Vincent Nicolaï, Rosine Guimbaud, Samira Icher, Nadim Farés, Janick Selves, Frédéric Chibon
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 35(12)
The outcome of stage II-III colorectal cancer (CRC) is highly variable and therapeutic choice is currently based on TNM staging with a few additional biomarkers. However, studies show that some stage III patients have a better prognosis than some sta
Publikováno v:
Bulletin du Cancer. 108:67-79
Compared with other breast cancer subtypes, patients with metastatic triple-negative breast cancer (TNBC) are younger and have a worst overall survival with a median of 15 to 18 months. These tumors have long suffered from a purely negative definitio
Autor:
Charlotte Vaysse, C. Massabeau, Jean Louis Lacaze, Henri Roché, Cyprian Chira, Eleonora De Maio, Julia Gilhodes, Mony Ung, Eva Jouve, Florence Dalenc, Thomas Filleron, F. Izar, Raphaëlle Duprez-Paumier, Anne Pradines, Vincent Nicolaï, Camille Franchet, Gabrielles Selmes
Publikováno v:
Cancer Research. 80:P2-18
Background: Currently, clinico-pathological characteristics (CPC) such as tumor size, lymph node status, tumor grade, proliferation, lympho-vascular invasion and percentage of cells expressing estrogen (ER) and progesterone receptors (PR) are usually
Publikováno v:
Bulletin du cancer. 108(1)
Compared with other breast cancer subtypes, patients with metastatic triple-negative breast cancer (TNBC) are younger and have a worst overall survival with a median of 15 to 18 months. These tumors have long suffered from a purely negative definitio
Autor:
Alexandre de Moura, Perrine Vuagnat, Benjamin Renouf, Jean-Yves Pierga, Delphine Loirat, Pauline Vaflard, Charline Lafayolle de la Bruyère, Natacha Chaumard-Billotey, Nawale Hajjaji, Sylvain Ladoire, Sandrine Dabakuyo, Anne Patsouris, Jean Sébastien Frenel, Vincent Nicolai, Marie Alexandre, Nadine Dohollou, Julien Grenier, Heloïse Bourien, François-Clément Bidard
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract Following the results of the IMpassion130 trial, an early access program (EAP) was opened in France, allowing patients with PD-L1-positive advanced triple negative breast cancer (aTNBC) to receive a combination of paclitaxel and atezolizumab
Externí odkaz:
https://doaj.org/article/32a11dfa386a4c37a6ba7f6ce998b444